Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer...
Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer Related Fibrosis
The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BIOMARKERIGF
Identification of Clinically Useful Biomarkers for IGF I Rec...
799K€
Cerrado
artFibro
Artifying fibroblasts: Perturbation modelling in the lung tu...
2M€
Cerrado
PDC2022-133476-I00
ESTUDIO DE VALIDACION Y VALORIZACION EN EL MERCADO DE EPICAR...
148K€
Cerrado
BioFlow
The development of a predictive biomarker for immunotherapy...
150K€
Cerrado
PID2020-116808RB-I00
BIOMARCADORES BIOFISICOS Y MACHINE LEARNING PARA UNA PRUEBA...
182K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for the diagnosis and treatment of bone marrow fibrosis related to blood cancer. This proposed project builds upon recent findings of my deFiber ERC Starting Grant (Stg) project, where we identified this danger-associated molecular pattern complex as exactly as such a prognostic and predictive biomarker and importantly showed that targeting with a small molecular, oral, anti-cancer inhibitor reduced fibrosis but also the cancer cell burden, in the sense of a targetable biomarker.